• 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277300.
  • 2
    Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007; 13: S46524.
  • 3
    Kimura H, Iizasa T, Ishikawa A et al. Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients. Anticancer Res 2008; 28: 122938.
  • 4
    Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011; 73: 117.
  • 5
    Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 234657.
  • 6
    Schaft N, Willemsen RA, de Vries J et al. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol 2003; 170: 218694.
  • 7
    Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10: 46778.
  • 8
    Kondo M, Izumi T, Fujieda N et al. Expansion of human peripheral blood γδ T cells using zoledronate. J Vis Exp 2011; pii: 3182.
  • 9
    Fukuyama T, Hanagiri T, Takenoyama M et al. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res 2006; 66: 49228.
  • 10
    Sugaya M, Takenoyama M, Osaki T et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 2002; 122: 2828.
  • 11
    Szymczak AL, Workman CJ, Wang Y et al. Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol 2004; 22: 58994.
  • 12
    Kitamura T, Koshino Y, Shibata F et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 2003; 11: 100714.
  • 13
    Sugaya M, Takenoyama M, Shigematsu Y et al. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. Int J Cancer 2007; 120: 105562.
  • 14
    Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 90915.
  • 15
    Wright SE, Rewers-Felkins KA, Quinlin IS et al. Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients – a phase I/II study. Immunol Invest 2010; 39: 57086.
  • 16
    Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000; 75: 23582.
  • 17
    Morgan RA, Dudley ME, Yu YY et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003; 171: 328795.
  • 18
    Hiasa A, Hirayama M, Nishikawa H et al. Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8 +  T cells. Gene Ther 2008; 15: 6959.
  • 19
    Hughes MS, Yu YY, Dudley ME et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 2005; 16: 45772.
  • 20
    Thomas S, Hart DP, Xue SA, Cesco-Gaspere M, Stauss HJ. T-cell receptor gene therapy for cancer: the progress to date and future objectives. Expert Opin Biol Ther 2007; 7: 120718.
  • 21
    Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67: 3898903.
  • 22
    Okamoto S, Mineno J, Ikeda H et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res 2009; 69: 900311.
  • 23
    Jitsukawa S, Faure F, Lipinski M, Triebel F, Hercend T. A novel subset of human lymphocytes with a T cell receptor-gamma complex. J Exp Med 1987; 166: 11927.
  • 24
    Yoshida Y, Nakajima J, Wada H, Kakimi K. γδ T-cell immunotherapy for lung cancer. Surg Today 2011; 41: 60611.
  • 25
    Todaro M, D'Asaro M, Caccamo N et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009; 182: 728796.
  • 26
    Kato Y, Tanaka Y, Tanaka H, Yamashita S, Minato N. Requirement of species-specific interactions for the activation of human γδ T cells by pamidronate. J Immunol 2003; 170: 360813.
  • 27
    Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 38492.
  • 28
    Hiasa A, Nishikawa H, Hirayama M et al. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes. Gene Ther 2009; 16: 6208.
  • 29
    Jungbluth AA, Busam KJ, Kolb D et al. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 2000; 85: 4605.
  • 30
    Shigematsu Y, Hanagiri T, Shiota H et al. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer 2010; 68: 10510.
  • 31
    Asamura H, Goya T, Koshiishi Y et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008; 3: 4652.